Management of patients with idiopathic pulmonary fibrosis in clinical practice: The INSIGHTS-IPF registry

European Respiratory Journal

Volumn 46, Issue 1, 2015, Pages 186-196

  Behr, Jürgen ^a   Kreuter, Michael ^b   Hoeper, Marius M ^c   Wirtz, Hubert ^d   Klotsche, Jens ^e   Kosche, Dirk ^f   Andreas, Stefan ^g   Claussen, Martin ^h   Grohé, Christian ⁱ   Wilkens, Henrike ^j   Randerath, Winfried ^j   Skowasch, Dirk ^k   Meyer, F Joachim ^l   Kirschner, Joachim ^m   Gläser, Sven ⁿ   Herth, Felix J F ^b   Welte, Tobias ^c   Huber, Rudolf Maria ^o   Neurohr, Claus ^o   Schwaiblmair, Martin ^p   Kohlhäufl, Martin ^q   Höffken, Gert ^f   Held, Matthias ^r   Koch, Andrea ^s   Bahmer, Thomas ^h   Pittrow, David ^t   more..

^a ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^f Fachkrankenhaus Coswig   (Germany)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^h Akademisches Lehrkrankenhaus Universität Schleswig Holstein   (Germany)

ⁱ Klinik fur Pneumologie   (Germany)

^j SAARLAND UNIVERSITY   (Germany)

^k UNIVERSITY HOSPITAL BONN   (Germany)

^l Munich Municipal Hospital   (Germany)

^m Center for Internal Medical Studies CIMS   (Germany)

ⁿ UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^o UNIVERSITY OF MUNICH   (Germany)

^p KLINIKUM AUGSBURG   (Germany)

^q ROBERT BOSCH GMBH   (Germany)

^r Abteilung für Innere Medizin   (Germany)

^s RUHR UNIVERSITY BOCHUM   (Germany)

^t DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTICOAGULANT AGENT; ANTIVITAMIN K; AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; OXYGEN; PIRFENIDONE; PREDNISONE; STEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE DURATION; DISEASE REGISTRY; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GERMANY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALKING DISTANCE TEST; BIOPSY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EXERCISE TEST; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGISTER; VITAL CAPACITY; X-RAY COMPUTED TOMOGRAPHY;

ACETYLCYSTEINE; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; EXERCISE TEST; FEMALE; GERMANY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PYRIDONES; REGISTRIES; STEROIDS; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84937407681     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00217614     Document Type: Article

References (36)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-748.
3. Antoniou KM, Margaritopoulos GA, Siafakas NM. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 2013; 22: 281-291.
4. Wilson JW, du Bois RM, King TE Jr. Challenges in pulmonary fibrosis: 8-the need for an international registry for idiopathic pulmonary fibrosis. Thorax 2008; 63: 285-287.
5. Blackwell TS, Tager AM, Borok Z, et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med 2014; 189: 214-222.
6. Ryerson CJ, Corte TJ, Collard HR, et al. A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J 2014; 44: 273-276.
7. Alpert JS. Are data from clinical registries of any value? Eur Heart J 2000; 21: 1399-1401.
8. Gitt AK, Bueno H, Danchin N, et al. The role of cardiac registries in evidence-based medicine. Eur Heart J 2010; 31: 525-529.
9. Behr J, Hoeper MM, Kreuter M, et al. Charakteristika und Versorgung der idiopathischen Lungenfibrose. Rationale fur das INSIGHTS-IPF-Register. [Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry.] Dtsch Med Wochenschr 2012; 137: 2586-2588.
10. Behr J, Hoeper M, Kreuter M, et al. Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res 2014; 1: e000010.
11. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-664.
12. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
13. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324-1343.
14. Quanjer PH, Stocks J, Cole TJ, et al. Influence of secular trends and sample size on reference equations for lung function tests. Eur Respir J 2011; 37: 658-664.
15. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005; 2: 105-110.
16. Kupferberg DH, Kaplan RM, Slymen DJ, et al. Minimal clinically important difference for the UCSD shortness of breath questionnaire. J Cardiopulm Rehabil 2005; 25: 370-377.
17. Ringbaek T, Martinez G, Lange P. A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD 2012; 9: 12-15.
18. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010; 104: 296-304.
19. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
20. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
21. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
22. Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2093-2101.
23. Behr J, Günther A, Ammenwerth W, et al. S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose. [German guideline for diagnosis and management of idiopathic pulmonary fibrosis.] Pneumologie 2013; 67: 81-111.
24. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
25. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J 2011; 37: 743-746.
26. Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1043-1047.
27. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304.
28. Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012; 40: 519-521.
29. Johnston ID, Prescott RJ, Chalmers JC, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997; 52: 38-44.
30. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180.
31. Collard HR, Tino G, Noble PW, et al. Patient experiences with pulmonary fibrosis. Respir Med 2007; 101: 1350-1354.
32. Peikert T, Daniels CE, Beebe TJ, et al. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med 2008; 102: 1342-1348.
33. Cottin V, Cadranel J, Crestani B, et al. Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologists. Respir Med 2014; 108: 195-202.
34. Wells AU, Behr J, Costabel U, et al. Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Respir J 2012; 39: 805-806.
35. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2005; 14: 589-595.
36. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58: 635-641.